Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis

• Status: Recruiting
• Trial end date: 2026-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborators: Beijing Anzhen Hospital, Capital Medicine University; Beijing Fangshan District Hospital of Traditional Chinese Medicine; Beijing Haidian Hospital; Beijing Luhe Hospital, Capital Medicine University; Beijing Tsinghua Changgeng Hospital; Miyun District of Peking University First Hospital; Peking University International Hospital; Peking University People's Hospital; Peking University Shenzhen Hospital; Peking University Third Hospital
• Treatments: Cholecalciferol; Vitamin D

Criteria

Inclusion Criteria:

• Medically stable and receiving peritoneal dialysis for > 1 month

• Older than 18 years old

• Serum 25(OH)D < 30ng/ml

• Adequate dialysis on evaluation with weekly Kt/V ≥ 1.5, and without clinical uremic symptoms

Exclusion Criteria:

• Receive Vitamin D2/D3 during the previous 12 months;

• History of allergic reaction to Cholecalciferol;

• Current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, HIV/AIDS;

• Acute systemic infection, cardiovascular disease, surgery, or trauma in the last month;

• A high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 6 months;

• History of kidney transplant;

• Hemodialysis combined with peritoneal dialysis currently;

• Pregnant or breastfeeding;

• Not suitable enrolled assessed by researchers, including patients who could not regular follow-up